There is much interest in defining the signals that initiate abnormal proliferation of cells in a variety of states characterized by the presence of mononuclear phagocytes. Since IL-I is a major secretory product of activated human monocytes we examined whether this cytokine can stimulate the growth of human vascular smooth muscle cells (SMC). Neither recombinant IL-1 (rIL-1) a (' 5.0 ng/ml) nor , (c 100 ng/ml) stimulated SMC growth during 2-d incubations under usual conditions. IL-1 did stimulate SMC to produce prostanoids such as PGE, or PGE2 that can inhibit SMC proliferation. When prostaglandin synthesis was inhibited by indomethacin or aspirin both rIL-1 a and 6 (2 1 ng/ml) markedly increased SMC growth. In longer-term experiments (7-28 d) rIL-1 stimulated the growth of SMC even in the absence of cyclooxygenase inhibitors. The addition of exogenous PGE, or PGE2 (but not PGFIa, PGFu, PGI2) to indomethacin-treated SMC blocked their mitogenic response to rIL-l. Antibody to IL-1 (but not to platelet-derived growth factor [PDGFI) abolished the mitogenic response of SMC to rIL-1. Exposure of SMC to rIL-1 or PDGF caused rapid (maximal at 1 h) and transient (baseline by 3 h) expression of the c-fos proto-oncogene, determined by Northern analysis. We conclude that IL-1 is a potent mitogen for human SMC. Endogenous prostanoid production simultaneously induced by IL-1 appears to antagonize this growthpromoting effect in the short term (2 d) but not during more prolonged exposures. IL-1 produced by activated monocytes at sites of tissue inflammation or injury may thus mediate both positive and negative effects on SMC proliferation that are temporally distinct.
Introduction
The control of cellular proliferation is a fundamental biological problem that has considerable practical importance in relation to certain human diseases. For example, the pathogenesis of atherosclerosis and hypertension involve abnormal proliferation of smooth muscle cells (SMC)' within the arterial A preliminary report ofthis work was presented as an abstract in 1987 (Clin. Res. 35 :297 A).
wall (1, 2) . Definition of factors that may regulate proliferation of these cells has received considerable attention over the last dozen years. The platelet was an early contender as the source of mitogens that stimulate the growth of SMC during atherogenesis (3) . However, in the cholesterol-fed animal, SMC proliferation commences while the endothelial monolayer that lines the vessel's lumen remains intact, and before the adherence and degranulation of platelets at the site of the lesion (4). These observations indicate that initiation of atherogenesis in vivo does not require products released from platelets.
Morphologic studies of the sequence of events in the wall of arteries of animals fed cholesterol have stimulated interest in the role of phagocytic leukocytes in plaque formation. Soon after initiation of cholesterol feeding, blood monocytes adhere to the arterial intima and diapedese through its yet intact endothelial monolayer (5) (6) (7) (8) (9) . Focal accumulations of lipid-laden macrophages in the intima characterize the fatty streak, the lesion that precedes the complicated fibrous plaque characteristic of advanced atherosclerosis, and that contains accumulations of SMC in addition to phagocytes (10, 1 1) . These observations have focused attention on monocyte products that may stimulate the proliferation of mesenchymal cells such as SMC (12, 13) .
One of the mitogens secreted by activated mononuclear phagocytes resembles platelet-derived growth factor (PDGF). Upon stimulation, human monocytes can transcribe the genes that encode both chains of PDGF and secrete material that cross reacts immunologically with PDGF purified from human platelets and that shares its mitogenic activity (14) (15) (16) . Monocytes also produce the mitogen transforming growth factor a (Madtes, D. K., E. W. Raines, K. S. Sakariassen, R. K.
Assoian, M. B. Sporn, G. I. Bell, and R. Ross , personal communication) as well as material that resembles fibroblast growth factor (FGF) (17) . Upon activation, these cells secrete large amounts of the multipotent mediator IL-1 (18, 19) . Among the many functions ascribed to the IL-1 family of molecules is the ability to stimulate the proliferation ofhuman fibroblasts (20) , although its mitogenic effects on these cells can be weak or inconsistent (21) . IL-1 does have a degree of sequence homology with the acidic FGF family (22) . Therefore, it was of interest to determine if IL-l also promoted the growth of human vascular SMC and might thus participate in the abnormal proliferation of this cell type that occurs early in atherogenesis.
In previous studies we failed to demonstrate a mitogenic effect of IL-1 on vascular SMC from a variety of species generally studied over a 2-d period (23) . IL-1 characteristically stimulates the production of prostaglandins from target tissues, and SMC also respond to IL-I by increased production of PGE2 (24) (25) (26) . Since prostaglandins of the E sernes can inhibit mitogen-induced proliferation of cultured vascular SMC (27) , in our previous experiments endogenous prostanoids induced by IL-1 might have masked a direct mitogenic effect of this hormone. Our earlier study of the proliferative action of IL-1 on mesenchymal cells used material purified from activated human monocytes that contained an incompletely defined mixture ofthe two known species of human IL-1, a and f3. The present study used homogenous preparations of IL-1 a and ,B produced by recombinant DNA technology from genes cloned from human monocytes (28) (29) (30) to reexamine the possible mitogenic effect of IL-l on vascular SMC during longer periods of exposure, and under conditions that prevented the synthesis of endogenously produced prostanoids.
Methods
Cell preparation, culture, and characterization. SMC were prepared from human saphenous veins by explant outgrowth techniques (31) . The saphenous vein specimens were trimmnings obtained at coronary artery bypass surgery. This use of usually discarded tissue was approved by the Human Investigation Review Committee of New England Medical Center. The cell cultures were maintained in DME buffered with Hepes (25 mM) (M. A. Bioproducts, Walkersville, MD). Very low concentrations of bacterial endotoxin (< 100 pg/ml) can stimulate endogenous IL-l production by these cells (32) . Endotoxin contamination of tissue culture reagents could thus confound the results of study of the effects of exogenous recombinant IL-I (rIL-l) preparations. Therefore, constituents of tissue culture media were screened for endotoxin contamination using the quantitative chromogenic limulus amoebocyte lysate assay (QCL 1000; M. A. Bioproducts). Only materials with endotoxin levels < 40 pgs per ml were used in these experiments. In addition, the endotoxin antagonist polymyxin B (10 ,ug/ml) was included in all experimental incubations.
These cells cultured from saphenous vein explants (passage 2 to 5) exhibited typical morphologic characteristics of vascular smooth muscle in vitro including a pattern ofgrowth in hills and valleys (31) . Even after three passages in culture the majority of these cells exhibited specific immunofluorescence when stained with a monoclonal antibody that selectively recognizes muscle forms of actin (HHF 35 (35) . Dr. Dinarello also supplied an ammonium sulfate (40% saturated) precipitate from rabbit anti-serum raised against human rIL-la. We prepared an IgG fraction from this material by protein A affinity chromatography.
Highly purified PDGF from human platelets was provided by Elaine W. Raines and Russell Ross (36) . These investigators also generously supplied us with goat anti-human PDGF IgG. The probe used to detect c-fos mRNA was a 1-kb Eco RI fragment of v-fos proviral DNA (37) . The cDNA probe used to detect ,3-tubulin transcript was a highly conserved I kb segment of a rat #l-tubulin gene from pSP-6 (25, (43) (44) (45) (Fig. 1, A and B, open squares). These results agree with our previous studies that used IL-1 purified from activated human blood monocytes (23) . IL-l stimulates prostanoid production by SMC, and certain prostaglandins can inhibit the proliferative response of these cells to PDGF (27) . Therefore, we performed this experiment in parallel on cells incubated with the cyclooxygenase inhibitor indomethacin at a concentration (1 ,ug/ml) that completely blocks the synthesis of PGE2 by these cells (Table I ) (26) . Under this condition, both species of rIL-1 increased TdR incorporation even at the lowest concentration tested (Fig. 1, A and B, closed squares).
Thymidine incorporation alone is a potentially misleading index ofcell proliferation and may not reflect the actual rate of 7,064+911 ence of FCS (5%), which contains mitogens such as PDGF. Therefore, these experiments did not determine whether IL-1 potentiated PDGF or other serum-associated mitogens or could stimulate proliferation of HSVSMC in the absence of other growth factors. To address this issue we performed additional experiments that exposed HSVSMC cultures in parallel to rIL-la (1 ng/ml) with or without indomethacin in a variety of medium supplements. As before, rIL-1 stimulated TdR incorporation by HSVSMC incubated with FCS (5 or 2%) only in the presence of indomethacin (Fig. 3, crosshatched bars) . In the absence of IL-1, the lower concentration of FCS (2%) stimulated less TdR incorporation than did FCS (5%) (Fig. 3 , compare darkly and lightly crosshatched bars). Other conditions in this experiment used plasma-derived serum (PDS) prepared from horse blood and obtained commercially (HyClone Laboratories, Logan, UT). This material is prepared in a manner that limits the concentrations of coagulation-associated mitogens including PDGF (47) . In pilot experiments this lot of PDS caused little or no growth of human or bovine vascular SMC, but supported the proliferation of bovine aortic SMC after the addition of highly purified PDGF (data not shown). Baseline measurements showed that PDS alone caused less TdR incorporation than did equivalent concentra- tions of FCS. rIL-la added to medium containing PDS (5 or 2%) caused an approximately threefold increase in TdR incorporation in the presence of indomethacin (Fig. 3, stippled  bars) . This experiment also evaluated the ability of rIL-1 to stimulate TdR incorporation in HSVSMC cultures incubated in serum-free chemically defined medium supplemented with insulin (1 j,M) and transferrin (5 jig/ml) (IT). rIL-1 stimulated TdR incorporation in the absence of any serum-associated mitogen (Fig. 3, solid bars) . This finding shows that like PDGF, IL-1 stimulates cell proliferation in a simple medium that contains insulin or insulin-like factors (47, 48) .
rIL-is stimulate prostaglandin production by cultured human vascular SMC. IL-1 characteristically stimulates prostanoid production by target tissues. Several laboratories have found that monocyte-derived IL-1 increases prostaglandin production by vascular SMC (24) (25) (26) . We tested the effects of rIL-Is on the release of prostaglandins by adult human vascular SMC (Table I) . HSVSMC were incubated in 96-well plates in DME containing FCS (5%) for 2 d. Under basal conditions, these cells elaborated negligible amounts of PGE2, 6-keto PGFia (the stable metabolite of prostacyclin), or PGF2,a, the major products of the cyclooxygenase pathway in vascular smooth muscle (24, 25) . rIL-1 a or : augmented the release of these prostanoids manyfold (Table I) , at concentrations that stimulated TdR incorporation in an identical culture of these cells incubated in the presence of indomethacin (data not shown). The cyclooxygenase inhibitors, indomethacin (1 gg/ml) and aspirin (ASA, 0.1 mM), both inhibited the increases in prostaglandin production that were induced by IL-1 (Table I) .
Prostaglandins induced by IL-i inhibit the short-term mitogenic effect ofthis hormone on SMC. We hypothesized that rIL-ls failed to stimulate growth of HSVSMC because of simultaneous induction of the synthesis of growth-inhibitory prostanoids. To explore this possibility further we studied the relationship between the ability of rIL-1 to stimulate TdR incorporation by HSVSMC when prostanoid production was blocked to varying degrees. Indomethacin at 0.1 ,ug/ml completely prevented synthesis of PGE2 by IL-1-stimulated HSVSMC (Fig. 4, top) . This concentration of indomethacin also maximally augmented TdR incorporation in the same experiment. A concentration of indomethacin (0.01 ,ug/ml) that blocked PGE2 production incompletely permitted an intermediate rise in TdR incorporation in response to rIL-1 (Fig.  4, top) . Another inhibitor of cyclooxygenase, ASA, produced a similar pattern. Concentrations of ASA that incompletely inhibited PGE2 production also permitted only partial mitogenic response to rIL-1 (Fig. 4, bottom) . The reciprocal relationship between TdR incorporation and prostanoid production in IL-1-stimulated HSVSMC, demonstrated by the effect of these two different cyclooxygenase inhibitors at varying concentrations, supports the concept that endogenous prostanoids limit the mitogenic response of HSVSMC to IL-1 in such experiments.
As an additional test for this hypothesis, we added exogenous prostanoids to HSVSMC incubated with IL-13 (10 ng/ml) in the presence of a concentration of indomethacin (1 ,ug/ml) that abolished endogenous prostanoid production. Both exogenous PGE, and PGE2 (Sigma Chemical Co.) produced concentration-dependent inhibition of IL--induced HSVSMC cultures in 96-multiwell plates were incubated for 48 h in DME containing FCS (5%) alone or in the presence of rIL-I a (1.0 ng/ml) with the indicated concentrations of either indomethacin or ASA. In one set of identical cultures, the medium was collected after 48 h and analyzed for PGE2 by radioimmunoassay (n, n = 3, mean±SD). The values marked by asterisks may be underestimated since these PGE2 measurements were at the upper limit of the assay. In parallel cultures, TdR incorporation was measured during the last 24 h of the 48-h incubation (o, n = 8, mean±SD).
TdR incorporation (Fig. 5) . The range of concentration of these prostanoids tested (1-20 ng/ml) corresponded to those actually produced by cultured HSVSMC stimulated by IL-1 (Table I , Fig. 4 ). An independent experiment with rIL-1 a yielded almost identical results (data not shown HSVSMC in 12-multiwell plates were incubated in DME with FCS (5%) alone (A and D) or in the presence of rIL-I a at I ng/ml (B and E) or 10 ng/ml (C and F). After 5 d (A-C) the IL-I -treated SMC appeared elongated and bipolar by phase-contrast microscopy. There changes showed this accumulation macroscopically. At the end of this 4-wk experiment amido black staining confirmed these observations (Fig. 7, B and C) . Spectrophotometric quantitation of the amount of dye bound by these cell layers showed a fivefold increase in binding of the dye by the IL-Itreated cell layers (Fig. 7, graph) . Amido black probably stains the cell layer by binding to both intra-and extracellular proteins. This procedure may actually underestimate the amount of protein in the overgrown IL-1-treated wells because the dye may not have equal access to all cells in the multilayers characteristically formed by SMC in dense cultures. Note that in both the 2-d (Fig. 1 A) and 28-d (Figs. 6 and 7 ) experiments 1 ng/ml of rIL-1 a produced nearly as great an effect as a five-to tenfold higher concentration on all variables studied.
Comparison ofthe mitogenic effects ofIL-I and PDGF on human vascular SMC in culture. PDGF is the prototypical smooth muscle mitogen and accounts for much of the growth-promoting activity found in serum. PDGF has been highly purified from human platelets, and it was of interest to compare the mitogenic effects of PDGF and IL-1 on were frequent mitotic figures (white arrows). After 28 d of incubation (D-F) the cells maintained in DME with FCS alone retained their polygonal morphology while the cultures maintained in rIL-I a (E and F) show marked accentuation of the morphologic changes that were already observed after 5 d. It was difficult to focus on a single plane in these latter conditions as there were many layers of cells.
HSVSMC. PDGF produced near maximal increases in TdR incorporation at 5 ng/ml (Fig. 8) . The addition of indomethacin resulted in only a small increment in TdR incorporation under these conditions. IL-1 a produced a near maximal effect at 10 ng/ml in the presence of indomethacin (Fig. 8) . In the absence of indomethacin, IL-I did not stimulate TdR incorporation. The failure of indomethacin to increase significantly the mitogenic effect of PDGF may be because this mitogen does not induce PGE, or PGE2 release by HSVSMC. Two independent experiments showed no PGE2 production by these cells during a 48-h incubation with PDGF (0.1-5 ng/ml) (data not shown).
Studies with selective antibodies suggest that the mitogenic effects ofIL-I and PDGF on human vascular SMC are independent. Under some circumstances SMC themselves can express PDGF genes and secrete PDGF like growth-promoting activity (50) (51) (52) (53) . It was possible that IL-1 stimulated SMC proliferation indirectly by inducing endogenous PDGF production. We tested whether release of immunoreactive PDGF contributed to the IL-1-induced growth of HSVSMC in ex- Figure 8 . Comparison of the effects of PDGF and IL-I on TdR incorporation by HSVSMC. Cultures of HSVSMC in 96-multiwell plates were preincubated in IT for 48 h to arrest cell growth and to deplete any available serum-associated PDGF. The medium was then replaced with fresh IT that contained the indicated concentrations of rIL-la or PDGF highly purified from human platelets. Thymidine incorporation was measured during the second 24 h of a 48-h incubation in the presence or absence of indomethacin (1 ,ug/ml). Data are mean of eight observations. Fig. 6 were stained with amido black and photographed after the 28-d incubation. Condition A contained FCS alone, condition B contained rIL-a (1 ng/ml), and condition C contained rIL-la (10 ng/ml). Note the macroscopic changes in conditions B and C that corresponded to the phase microscopic observations presented in Fig. 6 , E and F. The bar graph beneath the photograph shows the amido black binding determined in extracts of these same cell layers. Data are mean±SD of three observations. ng/ml) and PDGF (1.5 ng/ml), in the presence of indomethacin (1 ,ug/ml), stimulated TdR incorporation by HSVSMC. In combination, PDGF and IL-1 produced additive effects (Fig.  9) . Addition of monospecific anti-human PDGF IgG completely inhibited the stimulatory effect ofPDGF on TdR incorporation, but did not block the effect of IL-I either alone or in the presence of added PDGF. In contrast, addition of anti-ILa IgG completely blocked the mitogenic effect of the interleukin, but did not affect the stimulatory effect of PDGF (Fig.  9) . The results of these antibody inhibition experiments support an effect of IL-1 on smooth muscle growth that is independent of mediation by release of immunoreactive PDGF.
IL-I rapidly and transiently induces expression ofthe c-fos proto-oncogene in vascular SMC. Addition of PDGF or fresh serum to fibroblasts or SMC rapidly induces mRNA that encodes the c-fos proto-oncogene. The product of this gene is a protein associated with the cell nucleus that may be involved in signaling the early events in commitment to cell division (54) (55) (56) (57) . If IL-1 were a mitogen for SMC, it should induce this proto-oncogene. Northern blotting experiments did not reveal c-fos transcript in RNA isolated from unstimulated HSVSMC. 15 min after addition of IL-1, c-fos mRNA was detected, and maximal levels were observed one-half hour after addition of the cytokine (Fig. 10) . By 3 h, c-fos mRNA was again undetected. Note that PDGF modulated levels of c-fos mRNA with an identical time course (Fig. 10) . The rapid kinetics of c-fos induction by IL-1, identical to that produced by PDGF, further supports a direct role for IL-1 as a signal for SMC division.
In addition, the lack of baseline c-fos expression and the rapid rise and fall of this mRNA indicate that HSVSMC incubated in IT are indeed growth arrested and respond synchronously to added mitogens.
Discussion
Proliferation of mesenchymal cells such as fibroblasts and smooth muscle contributes to fibrogenesis in wound healing as well as in certain important pathological processes. In the lung such mesenchymal cell multiplication occurs in interstitial fibrosis and granulomatous diseases (21) . An analogous situation may occur in some types of hepatic fibrosis (58) . Certain glomerulopathies also involve proliferative lesions (59) . In the context of the blood vessel, multiplication of vascular SMC is a key component in formation of the complicated atherosclerotic plaque (1) (2) (3) . This process may also play a role in the structural changes in blood vessels that may help sustain or contribute to progression of both systemic and pulmonary hypertension (2) . The presence of phagocytic leukocytes characterizes the early stages of the lesions in several of these pathological situations. Activated mononuclear cells are a likely source of mediators that signal cellular proliferation and the synthesis of macromolecules that contribute to fibrogenesis. PDGF-like mitogens account for part of the growth-promoting activity for mesenchymal cells produced by human macrophages (14) (15) (16) .
Another candidate is IL-1, a major secretory product of activated human monocytes. These cells express two distinct genes that encode protein products that have virtually indistinguishable biological activities, although they differ substantially in their physicochemical properties (60) . IL-I has an isoelectric point near neutrality and is the major form secreted by human monocytes upon activation; its message may account for several percent of the mRNA in these cells (28) . The other less abundant species, IL-1 a, has an isoelectric point of -5 (29, 30) .
IL-1I has a degree of sequence similarity with the acidic FGF/endothelial cell growth factor family (22, 61) , and IL-1 exhibits mitogenic effects on human fibroblasts under certain circumstances (20, 21) . We previously explored the possibility that IL-1 can also stimulate the growth of vascular SMC. In these experiments we failed to demonstrate a mitogenic effect of IL-1 derived from human monocytes on bovine, rabbit, or human vascular SMC during 2-d incubations (23) . We elected to reexamine this issue in the current study for several reasons.
It is now apparent that IL-1 is a potent inducer of prostanoid synthesis in SMC, and that prostanoids of the PGE series can inhibit the response of vascular SMC to such well-characterized mitogens as PDGF (27, 62) . The cloning of IL-1 genes and the production of rIL-1 species permits more defined experiments than were previously possible. In addition, there have been considerable improvements in the preparation and characterization of preparations of cultured adult human vascular smooth muscle available for such studies.
Inhibitory effects of prostaglandins on cell proliferation were first described in the early 1970s and have been noted in several contexts (21, 63, 64 (Fig. 4, A and B) . Addition of exogenous PGE1 or PGE2 to IL-1-stimulated HSVSMC, treated with indomethacin to block endogenous prostanoid synthesis, inhibited the mitogenic effect of rIL-1 (Fig. 5) . Although the antibody we used to measure PGE recognized PGEI as well as PGE2, since both of these compounds inhibit IL-1-induced SMC proliferation, this distinction is not critical to the interpretation of our findings. Thus, our data are consistent with a direct stimulatory effect of IL-1 on human vascular SMC growth that is counterbalanced in the short term by an "autocrine" inhibitory loop that involves prostaglandins.
Exposure of HSVSMC to rIL-1 for longer periods (1-4 wk) caused growth of HSVSMC even in the absence of cyclooxygenase inhibitors. The present data do not distinguish between several possible mechanisms for this "escape" phenomenon. The prolonged exposure of HSVSMC to rIL-1 could result in reduced production or responsiveness to prostaglandin. How (27) showed that PGE, or PGE2 reduced the fraction of nuclei labeled with tritiated TdR in PDGF-treated rat SMC, an effect unlikely to be due to altered TdR transport or pool specific activity. Bitterman et al. (21) also documented that PGE2 reduced labeling indices of fibronectin-stimulated fibroblasts.
Factors that regulate cell growth appear to act by a variety of mechanisms. Certain "growth factors" such as PDGF or FGF render cells competent to enter S phase. Other factors (e.g., insulin-like growth factor-I or somatomedin) do not themselves signal entry of the cells into S phase, but permit cells prepared for division by other signals to progress through the cell cycle (65, 48) . High concentrations of insulin such as those used in the defined serum-free medium denoted IT (Fig.  7) are not themselves mitogenic for SMC, but may act like somatomedin (40) . Thus, these results indicate that rIL-1 prepares SMC for entry into the cell cycle in a manner analogous to PDGF. The ability of IL-1 to increase c-fos mRNA levels rapidly and transiently in SMC provides further evidence that this cytokine may trigger early events in the commitment process for cell division. IL-l and PDGF increased c-fos mRNA with similar kinetics (Fig. 10) . Our experiments also show that the potency of IL-1 both in promoting growth of HSVSMC and in modulating c-fos message level is of the same order of magnitude as PDGF (Figs. 8-10 ).
The results of these studies highlight the potential complexity of growth control in the blood vessel wall. In addition to positive stimuli such as PDGF, IL-1, and other mitogens, the regulation of SMC growth probably includes inhibitory c-fos 28S> I'llpil'ilpipp'r.; "'' q w ,.:::-"---1 loops that involve prostanoids or heparin-like molecules (66) . Since IL-1 induces prostaglandin synthesis by mesenchymal cells this hormone can stimulate both positive and negative limbs of growth control. In intact animals, this dual effect would have the obvious advantage of limiting uncontrolled cell proliferations in response to these mitogens. Such simultaneous induction of stimulatory and inhibitory pathways is common in the fine regulation of many other important biological systems in vivo, including the neurotransmission, blood coagulation, and the immune response.
In the case of IL-1, the existence of a negative control loop is particularly significant in view of our recent finding that this family of hormones stimulates expression of its own genes by vascular smooth muscle and endothelial cells (26, 67) . Lovett and colleagues (68, 69) found that renal mesangial cells divide in response to monocyte-derived IL-1; this cell type can also express an IL-I gene (70) and elaborate IL-1-like activity that stimulates its own growth. Production of IL-I by target tissues such as smooth muscle and mesangium in vivo could set the stage for an autostimulatory inflammatory response that would amplify and extend to the detriment of the host. Since the local inflammatory response seldom propagates uncontrolled under normal circumstances in vivo, it is likely that such inhibitory control loops as we describe here do operate in the intact organism to modulate this response and limit positive feedback situations.
